US FDA approves Baxter and Halozyme’s Hyqvia to treat primary immunodeficiency
Hyqvia is a combination of Immune Globulin Infusion 10% (Human) (IG 10%) and Recombinant Human Hyaluronidase developed by Halozyme. The first subcutaneous immune globulin (IG) treatment is approved